levetiracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 185 Diseases   81 Trials   81 Trials   6476 News 


«12...1112131415161718192021...8182»
  • ||||||||||  Journal:  A point-prevalence study of off-label medication use in an Australian adult tertiary intensive care unit. (Pubmed Central) -  Dec 4, 2023   
    Most off- label medications were used for conventional (albeit not licensed) reasons, but nine out of 81 (11.1%) were not; for example, acetazolamide for hypertension, aminophylline for oliguria, and dexmedetomidine for seizures. Recognising the challenges of formally registering an indication with the Therapeutic Goods Administration, but also the value of reducing the incidence of medications used for potentially incorrect purposes, we suggest guideline endorsement of what constitutes standard critical care practice as an alternative to regulatory control.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Preclinical, Journal, Reflex:  Cenobamate enhances the anticonvulsant effect of other antiseizure medications in the DBA/2 mouse model of reflex epilepsy. (Pubmed Central) -  Nov 30, 2023   
    CNB, at 5 mg/kg, enhanced the antiseizure activity of ASMs, such as diazepam, clobazam, levetiracetam, perampanel, phenobarbital, topiramate, and valproate...The increase in antiseizure activity was associated with a comparable intensification in motor impairment; however, the therapeutic index of combined treatment of ASMs with CNB was more favorable than the combination with vehicle except for carbamazepine, phenytoin, and oxcarbazepine...Overall, this study shows the ability of CNB to counteract generalized reflex seizures in mice. Moreover, our data documented an evident synergistic antiseizure effect for the combination of CNB with ASMs including phenobarbital, benzodiazepines, valproate, perampanel, topiramate, and levetiracetam.
  • ||||||||||  Enrollment open:  Antiseizure Medication in Seizure Networks at Early Acute Brain Injury (clinicaltrials.gov) -  Nov 29, 2023   
    P4,  N=54, Recruiting, 
    LEV is associated with behavioral agitation and headaches, which makes VPA a desirable alternative for patients suffering from these symptoms. Not yet recruiting --> Recruiting
  • ||||||||||  phenytoin / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
    Journal, Adverse events, Adverse drug reaction:  Analysis of Adverse Drug Reactions in Pediatric Patients with Epilepsy: An Intensive Pharmacovigilance Study. (Pubmed Central) -  Nov 25, 2023   
    The risk analysis showed an association between belonging to the younger groups and polytherapy with ADR presence and between polytherapy and malnutrition with severe ADRs. In addition, most of the severe ADRs were preventable, and most of the nonsevere ADRs were nonpreventable.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Journal:  The Primary Prevention of Poststroke Epilepsy in Patients With Middle Cerebral Artery Infarct: Protocol for a Randomized Controlled Trial. (Pubmed Central) -  Nov 24, 2023   
    P=N/A
    We anticipate that the intervention groups will experience a lower incidence and reduced severity of poststroke epilepsy compared to the control group after 18 months. We aim to establish evidence supporting the potential preventive effects of LEV and PER on poststroke seizures and epilepsy in patients with MCA infarction, as well as to explore the antiepileptogenic potential of both LEV and PER in patients with major ischemic strokes.
  • ||||||||||  levetiracetam / Generic mfg.
    Review, Journal:  A review of the pharmacology and clinical applications of levetiracetam in dogs and cats. (Pubmed Central) -  Nov 21, 2023   
    Although its use is becoming more common in veterinary medicine, its role as a first-line monotherapy in small animal epileptics remains to be determined. This review of the human and animal literature regarding LEV describes its role in epileptic people and animals as well as in other disease states and provides recommendations for clinical usage.
  • ||||||||||  levetiracetam / Generic mfg.
    Journal:  Biallelic variants in the synaptic vesicle glycoprotein 2?A are associated with epileptic encephalopathy. (Pubmed Central) -  Nov 21, 2023   
    Synaptic Vesicle Glycoprotein 2?A (SV2A) is a membrane protein of synaptic vesicles and the binding site of antiepileptic drug levetiracetam...Knock out mice models earlier had replicated the human phenotype observed in these two families. These findings support that biallelic loss of function variants in SV2A result in early onset intractable epilepsy in humans.
  • ||||||||||  lacosamide / Generic mfg.
    Journal:  Neonatal Cardiac Arrest Following Lacosamide Treatment: A Case Report. (Pubmed Central) -  Nov 21, 2023   
    This is the first report of adverse cardiac event (AV block) in the setting of neonatal lacosamide use. Risk of future adverse cardiac events should be evaluated when determining the safety and efficacy of lacosamide in the neonatal population.
  • ||||||||||  lorazepam / Generic mfg., levetiracetam / Generic mfg., amphetamine / Generic mfg.
    Psychogenic Non-epileptic Seizure versus Epileptic Seizure in Rural Settings () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_1029;    
    Case Diagnosis: A 23-year-old male with complex partial status epilepticusCase Description or Program Description: A 23-year-old incarcerated male with history of amphetamine overdose, past suicidal attempts, and epilepsy had an episode of seizure-like activity just prior to being discharged...This later transitioned into status epilepticus and led to the administration of lorazepam and Keppra... In rural settings where EEG is not available, it is crucial to know alternatives.
  • ||||||||||  Subacute Neurologic Decline in a 4 Year Old with Sickle Cell Disease: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_974;    
    Families must be educated about the importance of preventative care in sickle cell disease. Rehabilitation physicians should be aware of the pathophysiology and complication of sickle cell disease as they may provide care for these patients after stoke, for pain management, or in the setting of bone marrow transplant.
  • ||||||||||  ticagrelor / Generic mfg., aspirin / Generic mfg., levetiracetam / Generic mfg.
    Left PCA Infarct Following off Pump CABG: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_777;    
    Patient who undergo CABG have several complications including stroke and it is important to be aware of these complications. In this case, early recognition and work-up led to appropriate treatment with dual anti platelet therapy.
  • ||||||||||  levetiracetam / Generic mfg.
    A Rare Case of Levetiracetam-induced Transaminitis () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_452;    
    Levetiracetam was discontinued and patient was started on phenytoin 100 mg 3 times daily. Despite not depending on any cytochrome P450 enzymes for metabolism, levetiracetam should be considered among the underlying cause of transaminitis, especially if other causes have been ruled out.
  • ||||||||||  sodium valproate / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
    Biomarker, Journal:  Validity of Serum Zinc/Copper Ratio as a Potential Novel Biomarker in Childhood Epilepsy. (Pubmed Central) -  Nov 14, 2023   
    0.7826 in distinguishing pharmacoresistant epilepsy, it produced 52% sensitivity, 64% specificity with AUC = 0.576 Low zinc and high copper levels were associated with childhood epilepsy especially those with pharmacoresistant type and treated with Oxcarbazepine. Zinc/copper ratio might be a potential biomarker in diagnosing childhood epilepsy and to some extent in predicting pharmacoresistant type.
  • ||||||||||  levetiracetam / Generic mfg.
    Journal:  Neuronal activity promotes glioma progression by inducing proneural-to-mesenchymal transition in glioma stem cells. (Pubmed Central) -  Nov 14, 2023   
    Levetiracetam, an antiepileptic drug, reduced the neuronal production of miR-184-3p-enriched exosomes, inhibited GSC PMT, and increased radiosensitivity of tumors to prolong survival in xenograft mouse models. Together, these findings indicate that exosomes derived from active neurons promote glioblastoma progression and radioresistance by inducing PMT of GSCs.
  • ||||||||||  sodium valproate / Generic mfg., levetiracetam / Generic mfg., diazepam / Generic mfg.
    Journal:  Paraneoplastic anti-GAD65 extralimbic encephalitis presented with epilepsy: A case report. (Pubmed Central) -  Nov 11, 2023   
    Future information strategies should aim to reach these professions, and support their information need on this topic. Anti-GAD65 autoimmune encephalitis can be extralimbic, can present with isolated epilepsy, and extralimbic anti-GAD65 encephalitis can occur with an underlying malignancy.
  • ||||||||||  Journal, Monotherapy, Real-world evidence, Real-world:  Anti-Seizure Monotherapy and Early Abortion Under Real-World Conditions. (Pubmed Central) -  Nov 10, 2023   
    Although the sample size of our study was small, these results indicate that the use of anti-seizure monotherapy in pregnant epilepsy patients may not increase the risk of early miscarriage. Larger prospective studies are needed for sufficient statistical analysis.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai
    Review, Journal:  Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies. (Pubmed Central) -  Nov 8, 2023   
    Finally, we identify and detail five active studies, including two clinical trials of levetiracetam in the respective treatment of cognition and neuropsychiatric features of AD, a study characterizing the prevalence of epilepsy in AD via prolonged EEG monitoring, a study characterizing AD biomarkers in late-onset epilepsy, and a study evaluating hyperexcitability in AD. These ongoing trials may guide future clinical decision-making and the development of novel therapeutics.
  • ||||||||||  lidocaine topical / Generic mfg., levetiracetam / Generic mfg.
    Review, Journal:  A Review on the Management of Peripheral Neuropathic Pain Following Breast Cancer. (Pubmed Central) -  Nov 6, 2023   
    In particular, comparative studies and the inclusion of patients across a range of pain intensities will be essential to developing a treatment algorithm for PMPS. In conclusion, current management for these patients should be tailored to their individual requirements.
  • ||||||||||  lacosamide / Generic mfg., atorvastatin / Generic mfg., levetiracetam / Generic mfg.
    PK/PD data, Preclinical, Journal:  Differential Pharmacokinetic Interplay of Atorvastatin on Lacosamide and Levetiracetam on Experimental Convulsions in Mice. (Pubmed Central) -  Nov 5, 2023   
    This study has demonstrated that the plasma concentration of ATOR was potentiated in the presence of LACO, but not in the presence of LEVE and it has provided significant protection against both the electro and chemo-convulsive models in mice. This could be due to the symbiotic pharmacokinetic interplay of ATOR with LACO, and possibly, this interplay may interfere with sodium channel conductance.
  • ||||||||||  Journal:  Drug repurposing analysis for colorectal cancer through network medicine framework: Novel candidate drugs and small molecules. (Pubmed Central) -  Nov 3, 2023   
    Based on the gene module, polyethylene glycol, gallic acid, pyrazole, cordycepin, phenothiazine, pantoprazole, cysteamine, indisulam, valinomycin, trametinib, BRD-K81473043, AZD8055, dovitinib, BRD-A17065207, and tyrphostin AG1478 presented as drugs and small molecule candidates previously studied in the CRC. Lornoxicam, suxamethonium, oprelvekin, sirukumab, levetiracetam, sulpiride, NVP-TAE684, AS605240, 480743.cdx, HDAC6 inhibitor ISOX, BRD-K03829970, and L-6307 are proposed as novel drugs and small molecule candidates for CRC.
  • ||||||||||  levetiracetam / Generic mfg.
    Exploring synaptic vesicle protein function in human neurons using CRISPR/Cas9 gene editing (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_12719;    
    Our glutamatergic iNs generated from Syt1 or SV2A KO stem cells show predicted phenotypes previously associated with loss of Syt1 or SV2A, including desynchronization of neurotransmitter release with respect to action potentials and increased short-term synaptic facilitation, respectively. This model system in combination with targeted gene editing may serve as a valuable platform for uncovering enigmatic protein function and mechanisms of therapeutic action in human synapses.
  • ||||||||||  hydromorphone hydrochloride / Generic mfg., levetiracetam / Generic mfg.
    Adjunct treatments positively impact mortality and recovery in a mouse traumatic brain injury and nerve agent exposure polytrauma model. (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_10288;    
    J. Leighton, E. Miller, J. Janssen, & J. Sahargun were supported in whole or in part by an appointment to the Research Participation Program for the U. S. Army Medical Research and Development Command administered by the Oak Ridge Institute for Science Education (ORISE) through an agreement between the U. S. Department of Energy and U. S. Army Medical Research and Development Command.
  • ||||||||||  sodium valproate / Generic mfg., levetiracetam / Generic mfg., carbamazepine / Generic mfg.
    A BEHAVIOURAL AND BIOMARKER ASSESSMENT OF MOUSE CORNEAL KINDLING AS A MODEL FOR EPILEPSY, CNS NEUROINFLAMMATION AND GLIOSIS (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5777;    
    Cytokine analysis was also performed for biomarkers of inflammation, including TNF?, IL-1?, IL-6. Taken together, these data provide valuable insights into the corneal kindling process as it relates to behavioural changes and neuroinflammatory biomarkers - and consequently an approach to study novel treatments across these domains.
  • ||||||||||  ezogabine (XEN496) / Xenon
    Differential profile of anti-seizure medications in the rat amygdala-kindling model (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5775;    
    This study was intended to highlight translational aspects of the rat amygdala-kindling model to identify new entities with improved tolerability and efficacy on focal and generalized seizures. The combination of this model and a cross-over design will provide a decision-enabling screening platform for the identification of novel compounds for the prevention, treatment, and modification of epilepsy, wherein pharmacoresistant focal seizures constitute the greatest challenge for treatment.